Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:13 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 11,328 matching trials from the live ClinicalTrials.gov search.
Filters: Cleveland, Ohio Clear all
Completed Phase 1Phase 2 Interventional

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

NCT02076191
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
Ruxolitinib, Decitabine
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
St Louis, Missouri • Buffalo, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Nov 3, 2026, 9:13 AM EST
Recruiting Phase 3 Interventional

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

NCT07100990
View directory record Official record
Conditions
Optic Neuritis, Myelitis, Myelitis, Transverse
Interventions
High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 3 Interventional

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

NCT00003313
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Interventions
filgrastim, amifostine trihydrate, carboplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
244
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 191 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 2 Interventional

Stereotactic Radiation Therapy in Treating Patients With Brain Metastases

NCT00006259
View directory record Official record
Conditions
Metastatic Cancer
Interventions
stereotactic radiosurgery
Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 3 Interventional Results available

Clinical Trial in Females for Female Pattern Hair Loss

NCT01226459
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5% Minoxidil Topical Foam, Vehicle Topical Foam
Drug
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 1 Interventional

Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer

NCT00118261
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, erlotinib hydrochloride, fluorouracil, leucovorin calcium, oxaliplatin
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 3 Interventional Results available

EXTEND (Eltrombopag Extended Dosing Study)

NCT00351468
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag olamine (SB-497115-GR)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
23
States / cities
Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Nov 3, 2026, 9:13 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

NCT05074810
View directory record Official record
Conditions
Non Small Cell Lung Cancer, KRAS Activating Mutation
Interventions
avutometinib and sotorasib, avutometinib and sotorasib and defactinib
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Boulder, Colorado • Washington D.C., District of Columbia • Arlington Heights, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 3 Interventional Results available

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

NCT03296813
View directory record Official record
Conditions
Heart Failure
Interventions
Torsemide, Furosemide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,973 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
60
States / cities
Alexander City, Alabama • Huntsville, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Nov 3, 2026, 9:13 AM EST
Completed No phase listed Observational

A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors

NCT02978586
View directory record Official record
Conditions
Prostate-specific Membrane Antigen Positive Tumors, Prostate Cancer, Breast Cancer, Lung Cancer
Interventions
[Ga-68]PSMA PET/MR
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

NCT00976391
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide + insulin glargine, insulin glargine + preprandial lispro insulin
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
142
States / cities
Birmingham, Alabama • Dothan, Alabama • Gilbert, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 2Phase 3 Interventional Results available

Novel Experimental COVID-19 Therapies Affecting Host Response

NCT04924660
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
Interventions
TXA127, TRV027, Placebo, Fostamatinib
Drug
Lead sponsor
Sean Collins
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
51
States / cities
Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Nov 3, 2026, 9:13 AM EST
Completed No phase listed Observational

Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

NCT02014896
View directory record Official record
Conditions
Ischemic Stroke, Atrial Fibrillation, Transient Ischemic Attacks, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke of Basilar Artery, Cardioembolic Stroke
Interventions
Biomarker blood draw
Other
Lead sponsor
Ischemia Care LLC
Industry
Eligibility
18 Years and older
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
22
States / cities
Sacramento, California • San Francisco, California • Detroit, Michigan + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Nov 3, 2026, 9:13 AM EST
Completed No phase listed Observational

Pediatric Pain Rehabilitation Program

NCT01340261
View directory record Official record
Conditions
Pediatric Chronic Pain
Interventions
Questionnaires
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 3 Interventional Results available

Topical DHEA Against Vaginal Atrophy

NCT01846442
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA (0.25%), DHEA (0.5%), DHEA (1.0%)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Cleveland, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Nov 3, 2026, 9:13 AM EST
Terminated Phase 3 Interventional Results available

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

NCT02871297
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 18 Years
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Tucson, Arizona • Wichita, Kansas • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 1 Interventional

A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure

NCT00662610
View directory record Official record
Conditions
Osteoarthritis, Hypertension
Interventions
naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
29
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Nov 3, 2026, 9:13 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

Cycling Study With the Axonics System

NCT05543382
View directory record Official record
Conditions
Overactive Bladder Syndrome, Urinary Urge Incontinence, Sacral Neuromodulation
Interventions
Axonics System
Device
Lead sponsor
Axonics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Naples, Florida • New Orleans, Louisiana • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Nov 3, 2026, 9:13 AM EST
Active, not recruiting Not applicable Interventional

Endoscopic Myotomy of the Pylorus To Improve Emptying and Symptoms Trial

NCT05039424
View directory record Official record
Conditions
Gastroparesis
Interventions
Endoscopic per-oral pyloromyotomy (POP), Diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption
Procedure
Lead sponsor
Matthew Allemang
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 2 Interventional Results available

A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)

NCT00336323
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Laser Photocoagulation, Bevacizumab
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Loma Linda, California • Palm Springs, California • Santa Barbara, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Nov 3, 2026, 9:13 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

NCT00947388
View directory record Official record
Conditions
Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
Interventions
Bendamustine Hydrochloride, Alemtuzumab
Drug · Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Nov 3, 2026, 9:13 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Using Decision Analysis to Enhance Decision-Making Regarding Prostate Cancer Screening

NCT03387527
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate cancer decision aid
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
55 Years to 69 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Nov 3, 2026, 9:13 AM EST
Completed Phase 3 Interventional

A Study Of Diflucan In Children With Ringworm Of The Scalp

NCT00645242
View directory record Official record
Conditions
Tinea Capitis
Interventions
fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Years to 12 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
28
States / cities
Montgomery, Alabama • Little Rock, Arkansas • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Nov 3, 2026, 9:13 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Inspire Home Study: Utilization of Home Monitoring During Therapy Optimization in Patients With an Inspire Upper Airway Stimulation System (Comparison of Home Sleep Testing vs. In-lab Polysomnography Testing)

NCT04416542
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Home Sleep Testing
Diagnostic Test
Lead sponsor
Inspire Medical Systems, Inc.
Industry
Eligibility
22 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
5
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Nov 3, 2026, 9:13 AM EST